STOK vs. NRIX, HRTX, ARCT, STTK, RVNC, FOLD, XENE, ARWR, PTCT, and DYN
Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Nurix Therapeutics (NRIX), Heron Therapeutics (HRTX), Arcturus Therapeutics (ARCT), Shattuck Labs (STTK), Revance Therapeutics (RVNC), Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Stoke Therapeutics (NASDAQ:STOK) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
Stoke Therapeutics received 50 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. Likewise, 72.99% of users gave Stoke Therapeutics an outperform vote while only 71.43% of users gave Nurix Therapeutics an outperform vote.
Stoke Therapeutics presently has a consensus price target of $20.57, indicating a potential upside of 40.71%. Nurix Therapeutics has a consensus price target of $21.88, indicating a potential upside of 38.89%. Given Stoke Therapeutics' higher probable upside, equities analysts plainly believe Stoke Therapeutics is more favorable than Nurix Therapeutics.
In the previous week, Stoke Therapeutics had 6 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Stoke Therapeutics and 6 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.59 beat Stoke Therapeutics' score of 0.43 indicating that Nurix Therapeutics is being referred to more favorably in the news media.
Stoke Therapeutics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.
Stoke Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -178.93%. Stoke Therapeutics' return on equity of -65.47% beat Nurix Therapeutics' return on equity.
Stoke Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Stoke Therapeutics beats Nurix Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Stoke Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stoke Therapeutics Competitors List
Related Companies and Tools
